Intellectus Partners LLC Trims Stake in Standard BioTools Inc. (NASDAQ:LAB)

Intellectus Partners LLC trimmed its holdings in shares of Standard BioTools Inc. (NASDAQ:LAB) by 3.6% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 404,702 shares of the company’s stock after selling 15,000 shares during the period. Intellectus Partners LLC’s holdings in Standard BioTools were worth $708,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its position in Standard BioTools by 188.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,445,083 shares of the company’s stock worth $4,719,000 after buying an additional 1,597,728 shares in the last quarter. State Street Corp boosted its holdings in shares of Standard BioTools by 26.7% in the 3rd quarter. State Street Corp now owns 5,495,136 shares of the company’s stock worth $10,606,000 after purchasing an additional 1,157,984 shares in the last quarter. Barclays PLC boosted its holdings in shares of Standard BioTools by 13.2% in the 3rd quarter. Barclays PLC now owns 3,228,360 shares of the company’s stock worth $6,231,000 after purchasing an additional 377,195 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Standard BioTools by 2.3% in the 3rd quarter. Geode Capital Management LLC now owns 6,949,717 shares of the company’s stock worth $13,415,000 after purchasing an additional 154,848 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Standard BioTools by 7.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 139,748 shares of the company’s stock worth $270,000 after purchasing an additional 9,995 shares in the last quarter. 53.74% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Casdin Partners Master Fund, L bought 4,820,959 shares of the stock in a transaction dated Friday, February 28th. The stock was bought at an average price of $1.06 per share, with a total value of $5,110,216.54. Following the purchase, the director now owns 58,846,780 shares in the company, valued at approximately $62,377,586.80. The trade was a 8.92 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 53.10% of the stock is currently owned by corporate insiders.

Standard BioTools Trading Up 2.7 %

LAB opened at $1.16 on Friday. Standard BioTools Inc. has a 12-month low of $0.99 and a 12-month high of $3.04. The stock has a 50-day moving average price of $1.52 and a 200-day moving average price of $1.77. The stock has a market capitalization of $431.82 million, a P/E ratio of -1.63 and a beta of 1.62.

Analyst Upgrades and Downgrades

Separately, KeyCorp cut Standard BioTools from an “overweight” rating to a “sector weight” rating in a report on Thursday, February 27th.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.